In this activity, it was requested an analysis of Capomulin, a pharmaceutical company drug, against other treatment regimens for squamous cell carcinoma (SCC). Here you can find a top-level summary of the study results:

• There were 248 mice participants in the study. 51% were male, 49% were female.

• Capomulin had a better performance than most of the treatment regimens, comparing the mean, median, variance, standard deviation and standard error of the tumor volume, except for Ramicane.

• Capomulin and Ramicane boxplots demonstrate they are better treatments when compared to Infubinol, and Ceftamin: the final tumor volume of the first group was smaller than the second group, despite Infubinol outlier.

• Comparing Capomulin and Ramicane, we notice similar results regarding the variance of the datasets, but Ramicane has a lower minimum, maximum and median final tumor volume values. However, Ramicane has a larger interquartile (spread of the middle 50% of the data).

• There is a strong correlation between the mouse weight and the average tumor volume for Capomulin: the Pearson correlation coefficient is 0.84, indicating the weight of the patient may play an important role when they are being treated with Capomulin. More data is needed to obtain a conclusive analysis.

—